Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|November 22, 2016
Flexible Manufacturing Solution
Author(s)Catalent
Catalent combines more than 80 years' manufacturing expertise, superior product quality and reliable supply, with a global network of facilities approved by 35 regulatory agencies, to provide flexible commercial and clinical manufacturing solutions. As a collaborator and innovative solution provider, the company has supported over half of all new molecular entities approved by the FDA in the last ten years.
Producing over 70 billion doses annually, Catalent provides manufacturing expertise for oral, sterile, biologic and inhaled dose forms for clients around the world. It has proven expertise in technology transfers and product launches, custom suite models, speciality handling (highly potent / DEA licenced compounds), and manufacturing technologies, leveraging its more than 30 global facilities with the capacity to support a wide range of small and large scale manufacturing requirements.
From a single, tailored solution, or multiple answers throughout a product's lifecycle, Catalent can improve the total value of treatments - from discovery to market.
Catalent. More products. Better treatments. Reliably supplied.™
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.